WO2004048519A3 - Treatment of mammalian reaction to ige interactions - Google Patents
Treatment of mammalian reaction to ige interactions Download PDFInfo
- Publication number
- WO2004048519A3 WO2004048519A3 PCT/US2003/037286 US0337286W WO2004048519A3 WO 2004048519 A3 WO2004048519 A3 WO 2004048519A3 US 0337286 W US0337286 W US 0337286W WO 2004048519 A3 WO2004048519 A3 WO 2004048519A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction
- mammalian
- treatment
- mammal
- ige
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03786972A EP1565210B1 (en) | 2002-11-21 | 2003-11-20 | Clostridial neurotoxin for use in the treatment of nasal congestion |
SI200332129T SI1565210T1 (en) | 2002-11-21 | 2003-11-20 | Clostridial neurotoxin for use in the treatment of nasal congestion |
AU2003295769A AU2003295769A1 (en) | 2002-11-21 | 2003-11-20 | Treatment of mammalian reaction to ige interactions |
US10/535,504 US7879340B2 (en) | 2002-11-21 | 2003-11-20 | Treatment of mammalian reaction of IgE interactions |
DK03786972.4T DK1565210T3 (en) | 2002-11-21 | 2003-11-20 | Clostridium neurotoxin for use in the treatment of nasal congestion |
CA2507115A CA2507115C (en) | 2002-11-21 | 2003-11-20 | Treatment of mammalian reaction to ige interactions |
ES03786972T ES2380662T3 (en) | 2002-11-21 | 2003-11-20 | Clostridial neurotoxin for use in the treatment of nasal congestion |
AT03786972T ATE540688T1 (en) | 2002-11-21 | 2003-11-20 | CLOSTRIDIAL NEUROTOXIN FOR USE IN THE TREATMENT OF NOSE CONGESTION |
US12/976,317 US8088360B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of infectious rhinitis in mammals with clostridia neurotoxins |
US12/976,421 US8088361B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of allergic rhinitis in mammals with Clostridia neurotoxins |
US12/976,483 US8092781B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of sinusitis in mammals with clostridia neurotoxins |
US12/976,459 US8715620B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of asthma in mammals with clostridia neurotoxins |
US13/304,092 US8349292B2 (en) | 2002-11-21 | 2011-11-23 | Treatment of allergic otitis media in mammals with Clostridia neurotoxins |
US14/223,056 US9314513B2 (en) | 2002-11-21 | 2014-03-24 | Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen |
US15/083,540 US9931383B2 (en) | 2002-11-21 | 2016-03-29 | Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen |
US15/942,767 US10369202B2 (en) | 2002-11-21 | 2018-04-02 | Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42774902P | 2002-11-21 | 2002-11-21 | |
US60/427,749 | 2002-11-21 |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10535504 A-371-Of-International | 2003-11-20 | ||
US10/535,504 A-371-Of-International US7879340B2 (en) | 2002-11-21 | 2003-11-20 | Treatment of mammalian reaction of IgE interactions |
US12/976,421 Continuation US8088361B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of allergic rhinitis in mammals with Clostridia neurotoxins |
US12/976,317 Continuation US8088360B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of infectious rhinitis in mammals with clostridia neurotoxins |
US12/976,459 Continuation US8715620B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of asthma in mammals with clostridia neurotoxins |
US12/976,483 Continuation US8092781B2 (en) | 2002-11-21 | 2010-12-22 | Treatment of sinusitis in mammals with clostridia neurotoxins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004048519A2 WO2004048519A2 (en) | 2004-06-10 |
WO2004048519A3 true WO2004048519A3 (en) | 2004-07-01 |
Family
ID=32393325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/037286 WO2004048519A2 (en) | 2002-11-21 | 2003-11-20 | Treatment of mammalian reaction to ige interactions |
Country Status (11)
Country | Link |
---|---|
US (9) | US7879340B2 (en) |
EP (1) | EP1565210B1 (en) |
AT (1) | ATE540688T1 (en) |
AU (1) | AU2003295769A1 (en) |
CA (2) | CA2854831C (en) |
CY (1) | CY1112621T1 (en) |
DK (1) | DK1565210T3 (en) |
ES (1) | ES2380662T3 (en) |
PT (1) | PT1565210E (en) |
SI (1) | SI1565210T1 (en) |
WO (1) | WO2004048519A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9700707B2 (en) | 2005-07-22 | 2017-07-11 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001270219A1 (en) * | 2000-06-28 | 2002-01-08 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
EP1565210B1 (en) * | 2002-11-21 | 2012-01-11 | Ira Sanders | Clostridial neurotoxin for use in the treatment of nasal congestion |
WO2004078201A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin |
US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
EP1906923B1 (en) | 2005-07-22 | 2018-01-24 | The Foundry, LLC | Systems and methods for delivery of a therapeutic agent |
EP2001491B1 (en) * | 2006-04-05 | 2016-06-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Anti-allergy compositions |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
WO2013009761A1 (en) | 2011-07-13 | 2013-01-17 | The Foundry, Llc | Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets |
CN102781467A (en) * | 2009-12-15 | 2012-11-14 | 艾拉·桑德斯 | Treatment of nasal and sinus disorders |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2020047159A1 (en) * | 2018-08-28 | 2020-03-05 | Ira Sanders | Skin therapeutics |
US20230000761A1 (en) * | 2019-12-13 | 2023-01-05 | Francesco BARBAGALLO | Botulinum toxin formulations and methods for intranasal delivery thereof for the treatment of allergic rhinitis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028171A1 (en) * | 1994-04-15 | 1995-10-26 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510339A (en) * | 1993-02-02 | 1996-04-23 | Mayo Foundation For Medical Education And Research | Method for the treatment of bronchial asthma by administration of topical anesthetics |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
US6822076B2 (en) * | 1998-05-13 | 2004-11-23 | Biotecon Therapeutics Gmbh | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
US7537773B1 (en) * | 1998-08-25 | 2009-05-26 | Botulinum Toxin Research Associates, Inc. | Chemodenervating pharmaceutical as anti-inflammatory agent |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6429189B1 (en) * | 1999-12-10 | 2002-08-06 | Botulinum Toxin Research Associates, Inc. | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases |
AU2001270219A1 (en) * | 2000-06-28 | 2002-01-08 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
EP1565210B1 (en) | 2002-11-21 | 2012-01-11 | Ira Sanders | Clostridial neurotoxin for use in the treatment of nasal congestion |
WO2004078201A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin |
US20090232772A1 (en) | 2004-12-09 | 2009-09-17 | Shiro Amano | Human corneal endothelial cell-derived precursor cells, cellular aggregates, methods for manufacturing the same, and methods for transplanting precursor cells and cellular aggregates |
EP1906923B1 (en) * | 2005-07-22 | 2018-01-24 | The Foundry, LLC | Systems and methods for delivery of a therapeutic agent |
US7655243B2 (en) * | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
-
2003
- 2003-11-20 EP EP03786972A patent/EP1565210B1/en not_active Expired - Lifetime
- 2003-11-20 AU AU2003295769A patent/AU2003295769A1/en not_active Abandoned
- 2003-11-20 DK DK03786972.4T patent/DK1565210T3/en active
- 2003-11-20 ES ES03786972T patent/ES2380662T3/en not_active Expired - Lifetime
- 2003-11-20 WO PCT/US2003/037286 patent/WO2004048519A2/en not_active Application Discontinuation
- 2003-11-20 CA CA2854831A patent/CA2854831C/en not_active Expired - Lifetime
- 2003-11-20 AT AT03786972T patent/ATE540688T1/en active
- 2003-11-20 SI SI200332129T patent/SI1565210T1/en unknown
- 2003-11-20 CA CA2507115A patent/CA2507115C/en not_active Expired - Lifetime
- 2003-11-20 US US10/535,504 patent/US7879340B2/en active Active
- 2003-11-20 PT PT03786972T patent/PT1565210E/en unknown
-
2010
- 2010-12-22 US US12/976,317 patent/US8088360B2/en not_active Expired - Fee Related
- 2010-12-22 US US12/976,483 patent/US8092781B2/en not_active Expired - Fee Related
- 2010-12-22 US US12/976,459 patent/US8715620B2/en not_active Expired - Lifetime
- 2010-12-22 US US12/976,421 patent/US8088361B2/en not_active Expired - Fee Related
-
2011
- 2011-11-23 US US13/304,092 patent/US8349292B2/en not_active Expired - Lifetime
-
2012
- 2012-04-09 CY CY20121100351T patent/CY1112621T1/en unknown
-
2014
- 2014-03-24 US US14/223,056 patent/US9314513B2/en not_active Expired - Lifetime
-
2016
- 2016-03-29 US US15/083,540 patent/US9931383B2/en not_active Expired - Lifetime
-
2018
- 2018-04-02 US US15/942,767 patent/US10369202B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028171A1 (en) * | 1994-04-15 | 1995-10-26 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
Non-Patent Citations (1)
Title |
---|
SHAARI C M, ET AL: "RHINORRHEA IS DECREASE IN DOGS AFTER NASAL APPLICATION OF BOTULINUM TOXIN", OTOLARYNGOLOGY-HEAD AND NECK SURGERY, vol. 112, no. 4, April 1995 (1995-04-01), pages 566 - 571, XP002976784 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9700707B2 (en) | 2005-07-22 | 2017-07-11 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112621T1 (en) | CLOSTRIDIA NEUROTOTOXIN FOR USE IN NOSE CONSUMPTION TREATMENT | |
WO2001064751A3 (en) | High potency recombinant antibodies and method for producing them | |
NL300920I2 (en) | inotuzumab ozogamicin | |
BRPI0314814B8 (en) | antibody comprising a variant of fc | |
ME00232B (en) | Antibodies to opgl | |
PL375041A1 (en) | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors | |
EP1284286A4 (en) | Alpha-isomaltosyltransferase, process for producing the same and use thereof | |
DK609985D0 (en) | ADHESIN ANTIGENES, ANTIBODIES AGAINST THESE AND DNA FRAGMENTS WHICH ENCOD THE ANTIGENES | |
FR12C0004I2 (en) | ANTIBODIES TO HUMAN CTLA-4 ANTIGEN AND USE | |
WO1999066951A3 (en) | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | |
WO2004022718A3 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
ID24398A (en) | METHOD FOR PRODUCING L-AMINO ACID | |
BR0315161A (en) | Isolated antibody, isolated polynicleotide, vector, host cell, method of producing an antibody, and, composition | |
ATE360706T1 (en) | PEPTIDE ACCEPTOR LIGATION PROCEDURE | |
CY1112845T1 (en) | PRODUCTS OF 1-DEOXY-LACTONOGIRIMYKIN AND THEIR USE IN THE TREATMENT OF ATHLETIC LYSOSOMIC DISEASES THROUGH ENHANCEMENT OF LYSOSIM A | |
DE60134962D1 (en) | ANTI-CCR4 ANTIBODIES AND FRAGMENTS THEREOF | |
BRPI0410031A (en) | optimized fc variants and methods for their generation | |
DK1137430T3 (en) | Therapeutic for suppressing snoring sounds | |
WO2006116949A8 (en) | A new bacillus subtilis strain and its use in preparing medicine for treating thrombosis | |
NO20061470L (en) | Process for the preparation of gamma-carboxylated proteins | |
EP1354896A4 (en) | Novel monoclonal antibody | |
WO2009008414A1 (en) | Monoclonal antibody having neutralizing activity against mmp13 | |
WO2003020904A3 (en) | Methods of generating human cd4+ th1 cells | |
WO2003051927A3 (en) | Production of f(ab')2 fragments in mammalian cells | |
WO2006095180A3 (en) | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2006008462 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10535504 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2507115 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003786972 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003786972 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10535504 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |